Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coya Therapeutics (COYA) EPS (Weighted Average and Diluted) (2022 - 2025)

Coya Therapeutics' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.13 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 50.0% year-over-year to -$0.13; the TTM value through Sep 2025 reached -$1.11, down 70.77%, while the annual FY2024 figure was -$0.98, 24.05% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.13 at Coya Therapeutics, up from -$0.36 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.15 in Q4 2023 and bottomed at -$1.55 in Q3 2022.
  • The 4-year median for EPS (Weighted Average and Diluted) is -$0.35 (2023), against an average of -$0.5.
  • The largest annual shift saw EPS (Weighted Average and Diluted) skyrocketed 112.5% in 2023 before it tumbled 220.0% in 2024.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.2 in 2022, then surged by 112.5% to $0.15 in 2023, then crashed by 220.0% to -$0.18 in 2024, then rose by 27.78% to -$0.13 in 2025.
  • Per Business Quant, the three most recent readings for COYA's EPS (Weighted Average and Diluted) are -$0.13 (Q3 2025), -$0.36 (Q2 2025), and -$0.44 (Q1 2025).